BioMed Research International

Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics and Therapeutics


Publishing date
02 Jan 2015
Status
Published
Submission deadline
15 Aug 2014

Lead Editor

1Department of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, USA

2Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA

3Department of Lymphoma and Myeloma, Institute of Hematology, The Chinese Academy of Medical Sciences (CAMS) and The Peking Union Medical College (PUMC), Tianjin, China


Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics and Therapeutics

Description

Hematologic malignancies consist of cancers affecting blood, bone marrow, and lymph nodes. Taken together, Chronic lymphocytic leukemia, Chronic myelogenous leukemia, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, multiple myeloma and others account for 10% of all newly diagnosed cancers each year within the United States. Recent efforts have significantly expanded our understanding of the molecular and genetic makeup of these malignancies, resulting in the development of powerful antineoplastic therapies, increased patient quality of life and extended overall survival. Unfortunately, many patients relapse and develop therapeutically unresponsive malignancies and succumb to their disease. A key to overcoming drug resistance in hematologic malignancies is an increased understanding of molecular and genetic changes to cancerous cells that leads to drug resistance. Furthermore, future findings will guide researchers in the development of novel therapeutics capable of overcoming drug resistance.

We invite authors to submit original research and review articles aiming to improve our understanding of drug resistance or offer novel therapeutic approaches to overcome drug resistance in hematologic malignancies. In particular, we are interested in articles that explore molecular changes resulting in drug resistance in hematologic malignancies and therapeutic approaches intended to target altered molecules. Potential topics include, but are not limited to:

  • Recent developments in understanding molecular changes resulting in drug resistance
  • Development and testing of novel therapeutic strategies to overcome drug resistance
  • New models to study changes in pathway signaling that results in drug resistance
  • Identifying cellular molecules involved in drug resistance that can serve as prognostic biomarkers

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/biochemistry/drh/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2015
  • - Article ID 459052
  • - Research Article

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2

Lu Gao | Minjie Gao | ... | Jumei Shi
  • Special Issue
  • - Volume 2015
  • - Article ID 384575
  • - Editorial

Drug Resistance in Hematologic Malignancies: Induction Mechanisms, Genetics, and Therapeutics

Fenghuang Zhan | Maurizio Zangari | Lugui Qiu
  • Special Issue
  • - Volume 2015
  • - Article ID 623254
  • - Review Article

Smoldering Multiple Myeloma

Minjie Gao | Guang Yang | ... | Jumei Shi
  • Special Issue
  • - Volume 2015
  • - Article ID 484537
  • - Review Article

Constitutive NF-κB Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma

Francesco Turturro
  • Special Issue
  • - Volume 2015
  • - Article ID 787809
  • - Research Article

Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance

Xiaoyan Qu | Lijuan Chen | ... | Jianyong Li
  • Special Issue
  • - Volume 2014
  • - Article ID 273180
  • - Research Article

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity

Lingyao Meng | Kent Carpenter | ... | David J. Bearss
  • Special Issue
  • - Volume 2014
  • - Article ID 190629
  • - Research Article

Destabilization of Akt Promotes the Death of Myeloma Cell Lines

Yanan Zhang | Yunfeng Fu | ... | Jing Liu
BioMed Research International
 Journal metrics
Acceptance rate30%
Submission to final decision81 days
Acceptance to publication43 days
CiteScore2.410
Impact Factor2.197
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.